The rate of samples with CD8+ cells > 20% was slightly higher in metastatic tumor samples (31.3% [5 of 16 samples]) than in primary tumor samples (25.0% [8 of 32 samples]). This evidence concerns the gene CD8A and metastatic neoplasm.